<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hepatobiliary disorders in patients with inflammatory bowel disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hepatobiliary disorders in patients with inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hepatobiliary disorders in patients with inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gad Friedman, MD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain Bitton, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) is characterized by chronic or recurring inflammation of the gastrointestinal (GI) tract and is comprised of two major disorders: ulcerative colitis and Crohn disease. Ulcerative colitis affects the colon, whereas Crohn disease can involve any part of the GI tract. Patients with IBD may also have extraintestinal manifestations, and diseases of the liver and biliary tract are common in IBD. This topic is an overview of hepatobiliary disorders that occur in patients with IBD, including drug-induced hepatoxicity associated with IBD-related treatments. </p><p>The clinical manifestations, diagnosis, and treatment of ulcerative colitis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p></p><p>The clinical manifestations, diagnosis, and treatment of Crohn disease are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p></p><p>The dermatologic and ocular manifestations of IBD are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2168133497"><span class="h1">EPIDEMIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Abnormal liver biochemical tests are present in up to 30 percent of patients with IBD and do not correlate with bowel disease activity, while chronic liver disease affects approximately 5 percent of patients with IBD [<a href="#rid1">1</a>].</p><p>The pathogenesis of IBD-associated hepatobiliary disorders is unclear and may involve immunologic, genetic, and environmental factors [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4062.html" rel="external">"Genetic factors in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2260941862"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Hepatobiliary disease may be suspected in patients with IBD who have symptoms (eg, jaundice, pruritus, nausea, vomiting) or who are asymptomatic but have abnormal liver biochemical and/or function tests. </p><p>The initial evaluation includes obtaining a history to identify potential risk factors for liver disease (eg, alcohol use) and performing a physical examination to look for signs of chronic liver disease (eg, jaundice, ascites, spider telangiectasias). The clinical manifestations and diagnosis of chronic liver disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Subsequent testing is determined based on the information gathered from the history and physical examination as well as the pattern of test abnormalities. Elevations of liver enzymes often reflect hepatocellular injury to the liver (alanine aminotransferase, aspartate aminotransferase) or biliary obstruction (alkaline phosphatase). While an abnormal serum albumin or prothrombin time may reflect malnutrition in a patient with active IBD, these may be seen in the setting of impaired hepatic synthetic function  (<a class="graphic graphic_algorithm graphicRef78223" href="/z/d/graphic/78223.html" rel="external">algorithm 1</a>). The serum bilirubin in part measures the liver's ability to detoxify metabolites and transport organic anions into bile.</p><p>The evaluation of patients with IBD and abnormal liver tests (with or without symptoms) is similar to the evaluation for patients without IBD, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DRUG-INDUCED LIVER INJURY</span><span class="headingEndMark"> — </span>Multiple drugs used for treating IBD have been associated with liver injury; however, dose adjustment or drug discontinuation typically results in improvement [<a href="#rid3">3,4</a>]. The clinical manifestations, diagnosis, and general management of drug-induced liver injury are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.) </p><p class="headingAnchor" id="H386617467"><span class="h2">Immunomodulators</span></p><p class="bulletIndent1"><span class="glyph">●</span>Thiopurines – The clinical presentation of thiopurine hepatotoxicity varies from asymptomatic aminotransferase elevations to cholestatic hepatitis to rarely reported conditions such as hepatic sinusoidal obstruction syndrome or peliosis hepatis. (See  <a class="medical medical_review" href="/z/d/html/3603.html" rel="external">"Peliosis hepatis"</a> and  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Introduction'</a>.) </p><p></p><p class="bulletIndent1">Patients treated with thiopurines (<a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a>) are routinely monitored with liver biochemical testing, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dosing and monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – Mild elevations in aminotransferases are common in patients on methotrexate, while hepatic steatosis and fibrosis develop infrequently [<a href="#rid2">2</a>]. Hepatotoxicity due to methotrexate may result from direct damage to the hepatocytes through a dose-dependent mechanism [<a href="#rid5">5,6</a>]. </p><p></p><p class="bulletIndent1">Patients treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are advised to avoid alcohol, and folate supplementation is given [<a href="#rid7">7</a>]. The approach to monitoring and drug dose adjustments for patients on methotrexate are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Hepatotoxicity'</a> and  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p></p><p class="bulletIndent1">Liver biopsy is not routinely indicated for all patients on <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> maintenance therapy; however, identifying patients at risk for hepatotoxicity who may require liver biopsy is discussed separately. </p><p></p><p class="headingAnchor" id="H623590208"><span class="h2">Biologic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-tumor necrosis factor (anti-TNF) agents – Therapeutic antibodies against TNF alpha (eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) infrequently cause liver injury; however, possible effects range from mildly elevated transaminases (less than twice the upper limit of normal ) to acute hepatitis, or rarely, severe cholestatic liver disease [<a href="#rid8">8-13</a>]. Monitoring patients on anti-TNF therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Tumor necrosis factor inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Monitoring'</a>.) </p><p></p><p class="bulletIndent1">Adverse effects of anti-TNF agents are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-interleukin (anti-IL) 12/23 antibody – <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a>, an anti-IL 12/23 antibody, has been infrequently associated with transient mild-to-moderate aminotransferase elevations (less than five times the upper limit of normal) that resolved despite continuing therapy [<a href="#rid14">14</a>]. The adverse effects of ustekinumab are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15279.html" rel="external">"Treatment selection for moderate to severe plaque psoriasis in special populations", section on 'Ustekinumab'</a> and  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis", section on 'Ustekinumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-integrin antibodies – <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a>, an alpha-4-beta-7 integrin inhibitor, has been rarely associated with hepatic steatosis. Less than 2 percent of patients experience mild to moderate elevations in aminotransferases and/or bilirubin (≥3 times the upper limit of normal). In general, these abnormalities do not lead to discontinuation of the medication [<a href="#rid15">15</a>]. The adverse effects of vedolizumab are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Anti-integrin antibody therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1271127128"><span class="h2">Other drugs</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> – Tofacitinib is an orally administered nonselective Janus kinase (JAK) inhibitor that is used for treating moderate to severe ulcerative colitis. Tofacitinib has been associated with serum aminotransferase elevations that are typically transient and mild (less than twice the upper limit of normal) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib'</a>.) </p><p></p><p class="bulletIndent1">Laboratory monitoring for patients on maintenance therapy for moderate to severe ulcerative colitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> – Sulfasalazine may infrequently cause hepatocellular (elevated aminotransferases) or cholestatic enzyme (alkaline phosphatase) abnormalities, often related to a hypersensitivity reaction. Sulfasalazine is a prodrug of 5-aminosalicylic acid, which is used more commonly than sulfasalazine and does not have side effects that have been associated with sulfasalazine. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on 'Side effects'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">Ozanimod</a> – Ozanimod is an oral sphingosine-1-phosphate (S1P) receptor modulator that is used for treating moderate to severe ulcerative colitis. Ozanimod has been associated with transient liver enzyme elevations during therapy but has not been linked to severe liver injury [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2369173595"><span class="h1">INFECTION</span></p><p class="headingAnchor" id="H2270964257"><span class="h2">Pyogenic liver abscess</span><span class="headingEndMark"> — </span>Pyogenic liver abscess is a rare extraintestinal manifestation of Crohn disease; however, the clinical and laboratory findings (eg, fever, abdominal pain, diarrhea, leukocytosis) can mimic a disease flare. The diagnosis is confirmed by obtaining a purulent aspirate of a liver lesion identified by imaging [<a href="#rid18">18</a>]. The treatment of pyogenic liver abscess includes antibiotics and abscess drainage, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>.)</p><p>The mechanism of abscess formation in patients with IBD is unclear. It may be due to direct extension of an intra-abdominal abscess or possibly due to portal pyemia with secondary seeding in the liver parenchyma. Additional factors that may contribute to abscess formation include chronic glucocorticoid use, fistulizing disease phenotype, and abdominal surgery [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Features of transmural inflammation'</a>.)</p><p class="headingAnchor" id="H3791839535"><span class="h2">Reactivation of viral hepatitis</span><span class="headingEndMark"> — </span>Individuals with a history of hepatitis B virus (HBV) infection who receive immunosuppressive therapy (eg, biologic agents) are at risk for HBV reactivation and a flare of their HBV disease. This can occur upon drug withdrawal or between treatment courses. Prior to initiating biologic therapy, patients with IBD are screened for HBV infection, and pretreatment screening and vaccination for HBV are discussed in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Pretreatment screening'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p></p><p>Prevention, diagnosis, and management of HBV reactivation among patients receiving immunosuppressive therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">NONALCOHOLIC FATTY LIVER DISEASE</span><span class="headingEndMark"> — </span>Nonalcoholic fatty liver disease (NAFLD) is liver steatosis with no other cause of fat accumulation, and the prevalence of NAFLD in patients with IBD ranges from 33 to 50 percent [<a href="#rid19">19-22</a>]. Risk factors for NAFLD in patients with IBD include glucocorticoid use, older age, higher body mass index, and higher triglyceride levels [<a href="#rid19">19,20</a>]. The diagnosis and management of NAFLD are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults"</a>.) </p><p class="headingAnchor" id="H3945551834"><span class="h1">CHOLESTATIC LIVER DISEASE</span></p><p class="headingAnchor" id="H2763248952"><span class="h2">Primary sclerosing cholangitis</span><span class="headingEndMark"> — </span>Primary sclerosing cholangitis (PSC) is a chronic, cholestatic disease of the liver and bile ducts that is often progressive and characterized by inflammation, fibrosis, and stricturing of the intra- and extrahepatic bile ducts. PSC is closely associated with IBD (primarily ulcerative colitis), and patients with concurrent PSC and IBD have an increased risk of colorectal cancer. The epidemiology, clinical features, diagnosis, and management of IBD in patients with PSC are presented separately. (See  <a class="medical medical_review" href="/z/d/html/659.html" rel="external">"Primary sclerosing cholangitis: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/4055.html" rel="external">"Primary sclerosing cholangitis: Inflammatory bowel disease and colorectal cancer"</a>.) </p><p class="headingAnchor" id="H3433305828"><span class="h2">Primary biliary cholangitis</span><span class="headingEndMark"> — </span>Primary biliary cholangitis (PBC) is a disease characterized by progressive inflammatory destruction of interlobular bile ducts that results in cholestasis and cirrhosis with a strong association with antimitochondrial antibodies. There are multiple case reports of PBC in patients with ulcerative colitis [<a href="#rid23">23-26</a>]. The autoimmune features of both diseases and their common association with some HLA haplotypes suggest a similar genetic predisposition [<a href="#rid24">24,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a> and  <a class="medical medical_review" href="/z/d/html/3616.html" rel="external">"Pathogenesis of primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p class="headingAnchor" id="H322638769"><span class="h1">OTHER DISORDERS</span></p><p class="headingAnchor" id="H6"><span class="h2">Granulomatous hepatitis</span><span class="headingEndMark"> — </span>Granulomatous hepatitis is a rare complication of Crohn disease that has also been associated with medications for IBD (<a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>)  (<a class="graphic graphic_picture graphicRef64126" href="/z/d/graphic/64126.html" rel="external">picture 1</a>) [<a href="#rid28">28,29</a>]. Granulomas are generally asymptomatic, and prognosis is good. However, some patients with IBD and granulomatous hepatitis may have hepatomegaly and elevated alkaline phosphatase and/or aminotransferase levels. Diagnosis of and treatment (eg, glucocorticoids) for granulomatous hepatitis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3582.html" rel="external">"Evaluation of the adult patient with hepatic granuloma"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Hepatic amyloidosis</span><span class="headingEndMark"> — </span>Secondary (reactive or AA) amyloidosis is an uncommon complication of chronic inflammatory diseases, and the prevalence in patients with ulcerative colitis and Crohn disease is less than 1 percent [<a href="#rid30">30</a>]. It is more common in men with colonic involvement. Amyloid deposits can involve almost any organ, including the liver, resulting in asymptomatic hepatomegaly. (See  <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">"Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"</a>.)</p><p>Therapy is directed primarily to achieve IBD remission and control intestinal inflammation, thereby decreasing the release of the acute phase reactant serum amyloid A, which is the precursor of the amyloid fibrils in this condition. (See  <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">"Pathogenesis of AA amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a>.) </p><p>Case reports suggest clinical improvement with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> for patients with ulcerative colitis and with anti-TNF agents for patients with Crohn disease [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H1552114364"><span class="h2">Portal vein thrombosis</span><span class="headingEndMark"> — </span>Portal vein thrombosis is rarely associated with IBD; however, chronic inflammation, immobilization, and coagulation abnormalities seen in IBD may be risk factors [<a href="#rid33">33-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults"</a>.)</p><p class="headingAnchor" id="H2771735313"><span class="h1">GALLSTONES</span><span class="headingEndMark"> — </span>The prevalence of gallstones is increased in patients with ileal Crohn disease (or those who have had ileal resection) [<a href="#rid36">36</a>]. Gallstones are probably caused by the malabsorption of bile acids, which interferes with their enterohepatic circulation. This leads to depletion of bile salts and the formation of lithogenic bile. (See  <a class="medical medical_review" href="/z/d/html/662.html" rel="external">"Gallstones: Epidemiology, risk factors and prevention"</a>.)</p><p class="headingAnchor" id="H82880003"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal liver biochemical tests are common in patients with inflammatory bowel disease (IBD) and do not correlate with bowel disease activity, while chronic liver disease affects approximately 5 percent of patients with IBD. (See <a class="local">'Epidemiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatobiliary disease may be suspected in patients with IBD who have symptoms (eg, jaundice, pruritus, nausea) or who are asymptomatic but have abnormal liver biochemical and/or function tests. The initial evaluation includes obtaining a history to identify potential risk factors for liver disease (eg, alcohol use) and performing a physical examination to look for signs of chronic liver disease (eg, ascites). Subsequent testing is determined based on the information gathered from the history and physical examination as well as the pattern of test abnormalities  (<a class="graphic graphic_table graphicRef68475" href="/z/d/graphic/68475.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef78223" href="/z/d/graphic/78223.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple drugs used for treating IBD (eg, thiopurines) have been associated with hepatotoxicity; however, dose adjustment or drug discontinuation typically results in improvement. (See <a class="local">'Drug-induced liver injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyogenic liver abscess is a rare extraintestinal manifestation of Crohn disease; however, the clinical and laboratory findings (eg, fever, abdominal pain, diarrhea, leukocytosis) can mimic a disease flare. The diagnosis and treatment of pyogenic liver abscess is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with IBD and a history of hepatitis B virus (HBV) infection who initiate immunosuppressive therapy are at risk for HBV reactivation. Prior to initiating biologic therapy, patients with IBD are screened for HBV infection. (See <a class="local">'Reactivation of viral hepatitis'</a> above.)</p><p></p><p class="bulletIndent1">Prevention, diagnosis, and management of HBV reactivation among patients receiving immunosuppressive therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary sclerosing cholangitis (PSC) is a chronic, cholestatic disease of the liver and bile ducts that is often progressive and characterized by inflammation, fibrosis, and stricturing of the intra- and extrahepatic bile ducts. PSC is closely associated with IBD (primarily ulcerative colitis), and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/659.html" rel="external">"Primary sclerosing cholangitis: Epidemiology and pathogenesis", section on 'PSC and inflammatory bowel disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonalcoholic fatty liver disease (NAFLD) is liver steatosis with no other cause of fat accumulation, and the prevalence of NAFLD in patients with IBD ranges from 33 to 50 percent. Risk factors for NAFLD in patients with IBD include glucocorticoid use, older age, higher body mass index, and higher triglyceride levels. (See <a class="local">'Nonalcoholic fatty liver disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2984024703"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102:344.</a></li><li><a class="nounderline abstract_t">Fousekis FS, Theopistos VI, Katsanos KH, et al. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res 2018; 11:83.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13:1106.</a></li><li><a class="nounderline abstract_t">Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23:4102.</a></li><li><a class="nounderline abstract_t">Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43.</a></li><li><a class="nounderline abstract_t">Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451.</a></li><li><a class="nounderline abstract_t">Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160:622.</a></li><li><a class="nounderline abstract_t">Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41:972.</a></li><li><a class="nounderline abstract_t">Tobon GJ, Cañas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26:578.</a></li><li><a class="nounderline abstract_t">Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001; 76:84.</a></li><li><a class="nounderline abstract_t">Ierardi E, Della Valle N, Nacchiero MC, et al. Infliximab single administration followed by acute liver injury. Inflamm Bowel Dis 2006; 12:1089.</a></li><li><a class="nounderline abstract_t">Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44:e20.</a></li><li><a class="nounderline abstract_t">Hagel S, Bruns T, Theis B, et al. Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 2011; 49:38.</a></li><li class="breakAll">https://livertox.nlm.nih.gov/Ustekinumab.htm (Accessed on September 20, 2019).</li><li><a class="nounderline abstract_t">Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66:839.</a></li><li><a class="nounderline abstract_t">Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63:1150.</a></li><li><a class="nounderline abstract_t">Comi G, Selmaj K, Bar-Or A. Hepatic Safety of Ozanimod in Phase 3 Relapsing Multiple Sclerosis Trials (62). Neurology 2021; 96:62.</a></li><li><a class="nounderline abstract_t">Lin JN, Lin CL, Lin MC, et al. Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study. Liver Int 2016; 36:136.</a></li><li><a class="nounderline abstract_t">Bessissow T, Le NH, Rollet K, et al. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22:1937.</a></li><li><a class="nounderline abstract_t">Saroli Palumbo C, Restellini S, Chao CY, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis 2019; 25:124.</a></li><li><a class="nounderline abstract_t">Rojas-Feria M, Castro M, Suárez E, et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol 2013; 19:7327.</a></li><li><a class="nounderline abstract_t">Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36:417.</a></li><li><a class="nounderline abstract_t">Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol 2003; 9:878.</a></li><li><a class="nounderline abstract_t">Koulentaki M, Koutroubakis IE, Petinaki E, et al. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci 1999; 44:1953.</a></li><li><a class="nounderline abstract_t">Arai O, Ikeda H, Mouri H, et al. Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis. Nihon Shokakibyo Gakkai Zasshi 2010; 107:900.</a></li><li><a class="nounderline abstract_t">Ohge H, Takesue Y, Yokoyama T, et al. Progression of primary biliary cirrhosis after proctocolectomy for ulcerative colitis. J Gastroenterol 2000; 35:870.</a></li><li><a class="nounderline abstract_t">Onishi S, Sakamaki T, Maeda T, et al. DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994; 21:1053.</a></li><li><a class="nounderline abstract_t">Braun M, Fraser GM, Kunin M, et al. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol 1999; 94:1973.</a></li><li><a class="nounderline abstract_t">Namias A, Bhalotra R, Donowitz M. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 1981; 3:193.</a></li><li><a class="nounderline abstract_t">Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71:261.</a></li><li><a class="nounderline abstract_t">Meyers S, Janowitz HD, Gumaste VV, et al. Colchicine therapy of the renal amyloidosis of ulcerative colitis. Gastroenterology 1988; 94:1503.</a></li><li><a class="nounderline abstract_t">Serra I, Oller B, Mañosa M, et al. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis 2010; 4:269.</a></li><li><a class="nounderline abstract_t">Maconi G, Bolzacchini E, Dell'Era A, et al. Portal vein thrombosis in inflammatory bowel diseases: a single-center case series. J Crohns Colitis 2012; 6:362.</a></li><li><a class="nounderline abstract_t">Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.</a></li><li><a class="nounderline abstract_t">Landman C, Nahon S, Cosnes J, et al. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:582.</a></li><li><a class="nounderline abstract_t">Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267.</a></li></ol></div><div id="topicVersionRevision">Topic 4074 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100965" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Abnormal hepatic biochemistries in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29707074" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17455203" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28652663" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147616" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493586" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945303" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756190" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547695" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serious liver disease induced by infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11155419" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Infliximab-associated reversible cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075352" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Infliximab single administration followed by acute liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593165" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adalimumab-induced autoimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21176723" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Subacute liver failure induced by adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21176723" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Subacute liver failure induced by adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893500" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The safety of vedolizumab for ulcerative colitis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21584942" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hepatic Safety of Ozanimod in Phase 3 Relapsing Multiple Sclerosis Trials (62)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26012730" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27379445" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889226" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259964" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702985" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679954" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10548342" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ulcerative colitis associated with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530926" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Progression of primary biliary cirrhosis after proctocolectomy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7699227" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406274" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mesalamine-induced granulomatous hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6113258" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reversible sulfasalazine-induced granulomatous hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522802" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3360271" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Colchicine therapy of the renal amyloidosis of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122515" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405175" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Portal vein thrombosis in inflammatory bowel diseases: a single-center case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016749" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23385240" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Portomesenteric vein thrombosis in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464998" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
